

## Special Issue

# Advances of Personalized Medicine for Gastric Cancer

### Message from the Guest Editor

Precision medicine is reshaping the paradigm of cancer treatment, and the management of gastric cancer has also recently moved toward a tailored therapeutic approach. This Special Issue aims to highlight the most recent acquisitions around the molecular and cellular biology of gastric cancer, and it focuses on the most compelling advances in tailoring of systemic therapies in patients affected by this disease. The growing knowledge about the genomic landscape of gastric cancer has paved the way for the development of novel targeted drugs and the identification of relevant predictive factors. Beyond the introduction of anti-HER2 agents more than ten years ago and, more recently, anti-VEGF drugs, the most promising targets include claudin 18.2 and FGFR, but many trials are ongoing. Articles investigating genetic and epigenetic drivers or other significantly altered pathways, as well as preclinical or clinical studies focused on the molecular profiling, are welcome.

### Guest Editor

Dr. Valeria Merz

1. Digestive Molecular Clinical Oncology Research Unit, Università degli Studi di Verona, 37134 Verona, Italy
2. Medical Oncology Unit, Santa Chiara Hospital, 38122 Trento, Italy

### Deadline for manuscript submissions

closed (15 July 2023)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/115759](https://mdpi.com/si/115759)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).